Barely Significant
← all phrases

a slight trend

2,236 sentences · 2,236 papers · 4,853 search hits before verification · confirmed specimen

Sighted at

p<0.09

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

made a retrospective investigation to the feasibility of using MRI and 18 F-FDG-PET/CT in N staging and found that no significant difference was found between MRI and 18 F-FDG-PET/CT for the BLCA N staging but a slight trend of advantage of 18 F-FDG-PET/CT compared with MRI alone, which also indicated the value of the addition of PET information for the enhanced efficacy of N staging in BLCA.
Meta-analysis of vitamin C studies found no significant difference in C-reactive protein concentrations (−0.50; 95% CI: −3.63, 2.63; I 2 = 0%), intensive care unit stay duration (pooled mean difference: 1.44; 95% CI: 0.07, 2.81; I 2 = 0%), or mortality (pooled odds ratio: 0.55; 95% CI: 0.28, 1.09; I 2 = 0%), with a slight trend favoring reduced hospitalization duration (pooled mean difference: −2.37; 95% CI: −2.99, −1.76; I 2 = 49%).
In alignment with our flow cytometry analysis ( Figure 5 D), no pronounced changes in normalized protein abundances were detected for markers of oligodendrocyte maturation or myelination ( Figure 5 F, top), but in half of the ABEmax-treated mice (n = 3) we observed a slight trend for increased abundance of various markers for astrocyte maturation (subset 1 in Figure 5 F).
10 Concerns regarding secondary malignancies, such as acute myeloid leukemia and brain tumors, have been reported only in pediatric patients, with a slight trend favoring the control group. 10 Furthermore, there is a consideration that dexrazoxane may exacerbate myelosuppression caused by chemotherapeutic agents, as evidenced by a lower nadir in white blood cell count in the dexrazoxane group, although no significant differences were observed in the incidence rates of thrombocytopenia, neutropenia, and anemia. 10 Overall, the totality of available evidence robustly supports the use of dexrazoxane in adult patients at high risk for developing AIC.
[ 49 ], a slight trend towards an improvement in the glare sensitivity (mainly at medium frequencies) was observed from the first to the third month of supplementation (20 mg/day), and only after six months of lutein supplementation was a significant change observed in healthy subjects.